ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Dannah R. Miller, Matthew A. Ingersoll, Ming Fong Lin

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.

Original languageEnglish (US)
Pages (from-to)R195-R209
JournalEndocrine-Related Cancer
Issue number4
StatePublished - 2018


  • Cancer
  • Castration-resistant prostate
  • ErbB-2
  • ErbB-2 regulation
  • ErbB-2-targeting therapies

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research


Dive into the research topics of 'ErbB-2 signaling in advanced prostate cancer progression and potential therapy'. Together they form a unique fingerprint.

Cite this